WASHINGTON, May 19, 2022
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA)
today announced participation at Digestive Disease Week (DDW) 2022,
to be held in San Diego, CA and
online from May 21-24, 2022.
The following will be presented:
May 21, 2022
Presentation Title: "THE ROLE OF M1 TO M2 MACROPHAGE
POLARIZATION IN THE ETIOLOGY OF IDIOPATHIC GASTROPARESIS: GWAS
PERSPECTIVE"
Abstract Number: 3752409
Presenter: Dr. Sandra Paulina
Smieszek, Head of Genetics
Session Type: Plenary Session
Session Title: Late-Breaking Basic Science Abstract Plenary
Session Time: 2:00 PM to 3:30 PM
PDT
Presentation Time: 2:15 PM to 2:30 PM
PDT
May 23, 2022
Presentation Title: "ENRICHMENT OF PATIENTS WITH EHLERS DANLOS
SYNDROME IN IDIOPATHIC GASTROPARESIS – A GENE SET ENRICHMENT
ANALYSIS"
Abstract Number: 3696881
Presenter: Dr. Sandra Paulina
Smieszek, Head of Genetics
Session Type: Poster Session
Session Title: Cell Biology, Biochemistry and Integrative
Physiology
Session Time: 12:30 PM to 1:30 PM
PDT
For more information on DDW 2022, please refer to
https://ddw.org/.
About Vanda Pharmaceuticals Inc.
Vanda is a leading
global biopharmaceutical company focused on the development and
commercialization of innovative therapies to address high unmet
medical needs and improve the lives of patients. For more on Vanda
Pharmaceuticals Inc., please visit www.vandapharma.com and follow
us on Twitter @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original
content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-presentations-at-ddw-2022-301551750.html
SOURCE Vanda Pharmaceuticals Inc.